How to Use Glepaglutide
Complete guide to Glepaglutide dosing, administration, timing, and protocol recommendations.
Quick Overview
Glepaglutide is Zealand Pharma's long-acting GLP-2 analog for short bowel syndrome, built to be injected once or twice a week instead of daily like teduglutide. Its path has been bumpy. The FDA rejected it in December 2024 because the single phase 3 trial only worked at the twice-weekly dose, but Europe went the other way: in September 2026 the EMA's CHMP recommended approval under the name Zeydovio. As of late October 2026 the final European Commission decision is still pending, and the US needs another trial.
Dosing Guidelines
Common Dose
10 mg twice weekly (trial dose)
Frequency
Twice weekly
Dose Range
10 mg once or twice weekly tested; only twice weekly was significant
Note: These are phase 3 trial doses for SBS patients on IV support, given under specialist care with IV volume adjusted as absorption improves. Not a recommendation and not relevant to people without intestinal failure.
Administration Method
Subcutaneous injection (prefilled pen in the EU filing)
Best Time to Take
Same days each week (trial schedule)
The depot releases slowly over days, so a steady twice-weekly schedule keeps levels even. Clock time was not a factor in the trials.
Protocol Duration
24 weeks in EASE-1, with longer-term extension studies
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Injection site reactions
- •Abdominal pain
- •Nausea
- •Vomiting
- •Stoma changes and abdominal distension (GLP-2 class effect)
Frequently Asked Questions
What is the recommended dose for Glepaglutide?
10 mg twice weekly (trial dose)
How do you administer Glepaglutide?
Subcutaneous injection (prefilled pen in the EU filing)
When is the best time to take Glepaglutide?
Same days each week (trial schedule)
How long should you use Glepaglutide?
24 weeks in EASE-1, with longer-term extension studies
This information is for educational purposes only. Always consult with a healthcare professional before using any peptide. Dosing information is based on research literature and community reports, not medical advice.